Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells

Fig. 2

The effect of celecoxib and imatinib on human CML patient samples. a Mononuclear cells extracted from human CML patient samples and were treated with 0, 40, 60, 80, 100 μM celecoxib or 0, 1.6, 3.2, 6.4, 12.8 μM imatinib for 24, 48 h, then followed with MTT assay. Data were mean ± SD (n = 5). **p < 0.01, ***p < 0.001. b The sixth human CML patient sample was treated with 0, 40, 60, 80, 100 μM celecoxib for 24 h. Annexin V/PI assays was performed by flow cytometry

Back to article page